IDXX
Idexx Laboratories Inc
$535.38+1.15%
Setup
No setup
Buy Zone
$522.83-$548.97
Sector
Diagnostics & Research
Industry
Diagnostics & Research
38
Recommendation
Avoid
Avoid
Too many CANSLIM criteria failing.
IDXX chart
Loading chart…
ADX
Weak or Absent10.0Long Term
Range →Intermediate Term
Range →Short Term
Range →Overall Quality38
RS Rating
18
relative strength
Fundamentals
74
Solid fund-Q
Volume Demand
82
-34% vs avg
Technical Setup
38
3/8 checks
Industry/Theme
91
Diagnostics & Research
Trade Plan
Avoid
Entry
$522.83
Entry Zone
$522.83-$548.97
Stop / Risk
$481
RS Rating
18
Volume confirmed
Yes
Targets
$627.4 / $653.54
Breakout · IBD Setup
3 ✓ 5 ✗
Entry $522.83–$548.97Stop $481Target $627.4 / $653.54
Market regimeUptrend
Quality38
RS Rating18
Above 50-MA-4.08%
Above 200-MA-11.82%
VolumeConfirmed
In Buy ZoneNo
Not extendedOK
Invalidation · Close below stop
How this came together
38
MarketUptrend
SetupNo setup
ConfidenceExperimental · not backtested
Fund-Q74 · Solid
StatusAvoid
Stock Data
52-Week Range519 – 770
Price % Chg YTD-20.86%
Price % Chg 4wk-9.26%
50-Day Avg Vol0.6 Mil
P/E Ratio37.6
Market Cap$42B
SectorHealthcare
IndustryDiagnostics & Research
Company Fundamentals
EPS % Chg (Qtr)17.55%
Sales % Chg (Qtr)9.66%
EPS Growth 5y14.28%
Sales Growth 5y9.72%
Annual ROE74.21%
Gross Margin62.53%
Operating Margin32.12%
Net Margin25.03%
Debt / Equity0.68
Setup levels
Current price
$535.38
Pivot
$522.83
Distance to buy
-30.5%
52-week range
518.53-770
Trigger evidence
No active trigger evidence available.
Financial health checks
5/5
Return on equity above 15%
ROE 74.21%
Net margin above 10%
Net margin 25.03%
EPS growing quarter on quarter
EPS q/q 17.55%
Sales growing quarter on quarter
Sales q/q 9.66%
Debt to equity below 1.0
D/E 0.68
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE74.21%
vs sector +52.1%
Net margin25.03%
vs sector +8.0%
Gross margin62.53%
vs sector -4.1%
EPS growth q/q17.55%
vs sector +9.5%
Sales growth q/q9.66%
vs sector -8.9%
Debt / equity0.68
vs sector +0.04
Business quality
74
GradeSolid
EPS rating49
P/E37.6
Market cap$42B
IndustryDiagnostics & Research
Technical checks
Über 50-MA
Fail
Über 200-MA
Fail
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Pass
In Kaufzone
Fail
Nicht überextended
Pass
Über 21-EMA
Fail
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-09-06
Trigger date
—
Days on list
1
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.